Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

Summary p53 was discovered 45 years ago as an SV40 large T antigen binding protein,
coded by the most frequently mutated TP53 gene in human cancers. As a transcription …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer
regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

The p53 tumor suppressor protein has a plethora of cell-intrinsic functions and
consequences that impact diverse cell types and tissues. Recent studies are beginning to …

Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug
Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) …

Simple Summary Although immune check point inhibitors have been established as a new
paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or …